Indomethacin (sodium hydrate)
Indomethacin (Indometacin) sodium hydrateis a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium hydrateis has anticancer activity and anti-infective activity. Indomethacin sodium hydrateis can be used for cancer, inflammation and viral infection research[1][2][3].
Product Specifications
CAS Number
[74252-25-8]
Product Name Alternative
Indometacin (sodium hydrate)
UNSPSC
12352005
Hazard Statement
H300, H370
Target
Antibiotic; Bacterial; COX; Influenza Virus
Type
Reference compound
Related Pathways
Anti-infection; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/indomethacin-sodium-hydrate.html
Concentration
10mM
Purity
99.85
Solubility
DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : 25 mg/mL (ultrasonic)
Smiles
O=C(O[Na])CC1=C(C)N(C(C2=CC=C(Cl)C=C2)=O)C3=C1C=C(OC)C=C3.O.O.O
Molecular Formula
C19H21ClNNaO7
Molecular Weight
433.82
Precautions
H300, H370
References & Citations
[1]Riendeau D, et, al. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol. 1997 May;121 (1) :105-17.|[2]Eli Y, et, al. Comparative effects of indomethacin on cell proliferation and cell cycle progression in tumor cells grown in vitro and in vivo. Biochem Pharmacol. 2001 Mar 1;61 (5) :565-71.|[3]Amici C, et, al. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell Microbiol. 2015 Sep;17 (9) :1391-404.|[4]Helleberg L, et, al. Clinical Pharmacokinetics of indomethacin. Clin Pharmacokinet. 1981 Jul-Aug;6 (4) :245-58.|[5]Sabiu S, et, al. Indomethacin-induced gastric ulceration in rats: Protective roles of Spondias mombin a nd Ficus exasperate. Toxicol Rep. 2015 Jan 8:2:261-267.|[6]Danisman B, et, al, Carnosic Acid Ameliorates Indomethacin-Induced Gastric Ulceration in Rats by Alleviating Oxidative Stress and Inflammation. Biomedicines. 2023 Mar 9;11 (3) :829.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Nat Commun. 2025 Oct 2;16 (1) :8779.|ACS Appl Bio Mater. 2023 Jul 17;6 (7) :2816-2825.|Adv Sci (Weinh) . 2024 Dec 5:e2410360.|Am J Physiol Endocrinol Metab. 2024 May 1;326 (5) :E696-E708.|Andrology. 2024 May 22.|Antioxidants (Basel) . 2021 Aug 24;10 (9) :1333.|Appl Mater Today. 2023 Apr.|Biochem Biophys Res Commun. 2025 Aug 27:781:152551.|Biochem Biophys Res Commun. 2025 Jul 1:768:151920.|Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jul 7;1870 (6) :159659.|Biomaterials. 2022 Oct:289:121800.|Biomed Res Int. 2021 May 14:2021:5565748.|Bioorg Chem. 2022 Dec:129:106206.|bioRxiv. 2024 Nov 08.|bioRxiv. 2025 Jul 12:2025.07.08.663754.|bioRxiv. 2025 Jun 3:2025.06.01.657218.|Biotechnol Bioeng. 2021 Dec;118 (12) :4687-4698.|BMC Cancer. 2019 Dec 2;19 (1) :1166.|BMC Nephrol. 2024 Jul 15;25 (1) :226.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Transplant. 2025 Jan-Dec:34:9636897251376125.|Chem Mater. 2017, 29 (19) :8221-8238.|Chin J Nat Med. 2021 Oct;19 (10) :741-749.|Chin Med. 2023 Sep 7;18 (1) :113.|Clin Exp Pharmacol Physiol. 2025 Nov;52 (11) :e70081.|Clin Transl Med. 2021 Oct;11 (10) :e548.|Drug Des Devel Ther. 2025 Mar 19:19:2035-2050.|Drug Metab Dispos. 2025 Nov 10;53 (12) :100200.|Ecotoxicol Environ Saf. 2025 Jan 22:290:117765.|Ecotoxicol Environ Saf. 2025 Nov 15:307:119433.|Eur J Med Chem. 2021 Dec 5:225:113743.|Eur J Med Chem. 2023 Oct 5:258:115602.|Eur J Pharm Sci. 2023 Oct 1:189:106550.|Eur Rev Med Pharmacol Sci. 2020 Nov;24 (21) :11199-11211.|FEBS Open Bio. 2025 Jan;15 (1) :122-139.|Front Med. 2021 Apr 13:8:634882.|Front Physiol. 2021 Oct 28;12:770430.|Hepatology. 2023 Feb 1;77 (2) :456-465.|Immun Inflamm Dis. 2023 Feb;11 (2) :e787.|Immunity. 2025 Jun 10;58 (6) :1469-1483.e8.|Int Endod J. 2024 Sep;57 (9) :1228-1246. |Int J Med Sci. 2025 Mar 10;22 (8) :1773-1790.|Int J Nanomedicine. 2020 May 1;15:3087-3098. |Int J Pharm. 2017 Jan 30;517 (1-2) :19-24.|J Appl Toxicol. 2024 Oct;44 (10) :1528-1539.|J Ethnopharmacol. 2024 Aug 7:118660.|J Extracell Vesicles. 2024 Apr;13 (4) :e12426.|J Extracell Vesicles. 2024 Dec;13 (12) :e70025.|J Med Chem. 2021 Mar 11;64 (5) :2725-2738.|J Therm Biol. 2024 Jul 2:123:103906.|Langmuir. 2020 Sep 29;36 (38) :11374-11382.|Metabolites. 2025 May 14;15 (5) :324.|Mol Med Rep. 2023 Sep;28 (3) :164.|Mol Pharm. 2025 Aug 4;22 (8) :4969-4982.|Organogenesis. 2025 Dec;21 (1) :2460261.|Patent. US20180263995A1.|Pharmaceutics. 2024 May 29;16 (6) :731.|Phytomedicine. 2021 Nov:92:153751.|Phytomedicine. 2022 Apr:98:153928.|Phytomedicine. 2025 Oct 11:148:157400.|Phytother Res. 2025 Oct;39 (10) :4704-4717.|Res Sq. 2025 Nov 12.|Res Sq. 2025 Oct 27.|Research Square Preprint. 2020 Oct.|SSRN. 2025 Mar 31.|Toxicol Appl Pharmacol. 2017 May 15:323:44-52.|World J Gastroenterol. 2023 Oct 21;29 (39) :5452-5470.
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
